PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries
Standard
PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries. / Langenbruch, Anna; Mohr, Nicole; Andrees, Valerie; Kessens, Ihno; Reich, Adam; Czarnecka-Operacz, Magdalena; Puig, Luis; Dauden, Esteban; Iversen, Lars; Augustin, Matthias.
In: ACTA DERM-VENEREOL, Vol. 103, 31.08.2023, p. adv6532.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries
AU - Langenbruch, Anna
AU - Mohr, Nicole
AU - Andrees, Valerie
AU - Kessens, Ihno
AU - Reich, Adam
AU - Czarnecka-Operacz, Magdalena
AU - Puig, Luis
AU - Dauden, Esteban
AU - Iversen, Lars
AU - Augustin, Matthias
PY - 2023/8/31
Y1 - 2023/8/31
N2 - Enhanced treatment options for psoriasis and growing use of guidelines increased the potential to better quality of psoriasis care in Europe. The aim of the PsoBarrier EU study is to compare the quality and processes of psoriasis care in four European countries with different healthcare systems, based on validated quality indicators. This cross-sectional survey was conducted in dermatology centres in Denmark, Germany, Poland and Spain on 1,304 patients, using standardized patient and physician questionnaires. Measured by quality of psoriasis care indicators, patients in Poland had the most critical outcomes, such as the highest disease severity (Psoriasis Area and Severity Index; PASI) and lowest health-related quality of life (Dermatology Life Quality Index; DLQI). This indicates differences in psoriasis care, with Polish participants experiencing more severe psoriasis and its consequences. Differences in the healthcare systems, which create barriers to accessing treatments, could explain variations in quality of care.
AB - Enhanced treatment options for psoriasis and growing use of guidelines increased the potential to better quality of psoriasis care in Europe. The aim of the PsoBarrier EU study is to compare the quality and processes of psoriasis care in four European countries with different healthcare systems, based on validated quality indicators. This cross-sectional survey was conducted in dermatology centres in Denmark, Germany, Poland and Spain on 1,304 patients, using standardized patient and physician questionnaires. Measured by quality of psoriasis care indicators, patients in Poland had the most critical outcomes, such as the highest disease severity (Psoriasis Area and Severity Index; PASI) and lowest health-related quality of life (Dermatology Life Quality Index; DLQI). This indicates differences in psoriasis care, with Polish participants experiencing more severe psoriasis and its consequences. Differences in the healthcare systems, which create barriers to accessing treatments, could explain variations in quality of care.
KW - Humans
KW - Cross-Sectional Studies
KW - Quality of Life
KW - Europe
KW - Poland
KW - Psoriasis/diagnosis
U2 - 10.2340/actadv.v103.6532
DO - 10.2340/actadv.v103.6532
M3 - SCORING: Journal article
C2 - 37649411
VL - 103
SP - adv6532
JO - ACTA DERM-VENEREOL
JF - ACTA DERM-VENEREOL
SN - 0001-5555
ER -
